Scenesse Approval Buoys Clinuvel As It Fights Retrophin
The Australian firm Clinuvel sees good prospects for its dermatology product Scenesse, but at the same time is fighting off unwanted acquisition advances from a corporate suitor.
The Australian firm Clinuvel sees good prospects for its dermatology product Scenesse, but at the same time is fighting off unwanted acquisition advances from a corporate suitor.